罗沙司他治疗慢性肾脏病伴肾性贫血患者的效果及安全性研究OA
Study on the Efficacy and Safety of Roxadustat in the Treatment of Patients with Chronic Kidney Disease Complicated with Renal Anemia
目的:探究罗沙司他治疗慢性肾脏病伴肾性贫血患者的临床效果及安全性.方法:选取常州市第七人民医院 2021 年 1 月—2022 年 6 月收治的慢性肾脏病伴肾性贫血患者 96 例,用电脑随机数字法将其分为两组,每组 48 例.对照组予以临床常规治疗,研究组在对照组基础上增加罗沙司他治疗.比较两组疗效、炎症因子水平、贫血相关指标及用药安全性.结果:研究组治疗总有效率明显高于对照组(P＜0.05).治疗前,两组肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及超敏C反应蛋白(hs-CRP)、降钙素原(PCT)水平比较,差异均无统计学意义(P＞0.05);治疗后,两组TNF-α、IL-6、hs-CRP、PCT水平均低于治疗前,研究组均明显低于对照组(P＜0.05).治疗前,两组血红蛋白(Hb)、红细胞计数(RBC)、血清铁蛋白(SF)、铁调素(Hepc)水平比较,差异均无统计学意义(P＞0.05);治疗后,两组Hb、RBC、SF水平较治疗前均有明显升高,研究组均明显高于对照组(P＜0.05).两组治疗后Hepc水平较治疗前均有明显下降,研究组明显低于对照组(P＜0.05).两组不良反应发生率比较,差异无统计学意义(P＞0.05).结论:罗沙司他用于慢性肾脏病伴肾性贫血患者的临床治疗中,患者炎症及贫血情况有明显改善,临床疗效有明显提升,且用药较为安全可控.
Objective:To investigate the clinical effect and safety of Roxadustat in the treatment of patients with chronic kidney disease complicated with renal anemia.Method:A total of 96 patients with chronic kidney disease complicated with renal anemia admitted to Changzhou No.7 People's Hospital from January 2021 to June 2022 were selected and divided into two groups according to computer random number method,with 48 cases in each group.The control group was given routine clinical treatment,and the study group was given Roxadustat treatment on the basis of the control group.The efficacy,levels of inflammatory factors,anemia-related indexes and drug safety were compared between the two groups.Result:The total effective rate of the study group was significantly higher than that of the control group(P＜0.05).Before treatment,there were no significant differences in the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),hypersensitive C reactive protein(hs-CRP)and procalcitonin(PCT)between the two groups(P＞0.05).After treatment,the levels of TNF-α,IL-6,hs-CRP and PCT in both groups were lower than those before treatment,and those in the study group were significantly lower than those in the control group(P＜0.05).Before treatment,there were no significant differences in the levels of hemoglobin(Hb),red blood cell count(RBC),serum ferritin(SF)and hepcidin(Hepc)levels between the two groups(P＞0.05).After treatment,the levels of Hb,RBC and SF in both groups were significantly higher than those before treatment,and those in the study group were significantly higher than those in the control group(P＜0.05).The levels of Hepc in the two groups after treatment were significantly lower than those before treatment,and that in the study group was significantly lower than that in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:Roxadustat is used in the clinical treatment of patients with chronic kidney disease complicated with renal anemia,the inflammation and anemia situation of patients have been significantly improved,and the clinical efficacy has been significantly improved,and the drug is relatively safe and controllable.
赵乐;刘祥英
常州市第七人民医院(苏州大学附属常州老年病医院)肾内风湿科 江苏 常州 213011
慢性肾脏病肾性贫血罗沙司他炎症反应
Chronic kidney diseaseRenal anemiaRoxadustatInflammatory reaction
《中国医学创新》 2024 (001)
9-13 / 5
常州市卫健委科技项目(ZD202229)
评论